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Abstract
A potential therapeutic strategy for targeting cancer that has gained much interest is the inhibition of the ATP binding and
ATPase activity of the molecular chaperone Hsp90. We have determined the structure of the human Hsp90a N-terminal
domain in complex with a series of 5-aryl-4-(5-substituted-2-4-dihydroxyphenyl)-1,2,3-thiadiazoles. The structures provide
the molecular details for the activity of these inhibitors. One of these inhibitors, ICPD 34, causes a structural change that
affects a mobile loop, which adopts a conformation similar to that seen in complexes with ADP, rather than the
conformation generally seen with the pyrazole/isoxazole-resorcinol class of inhibitors. Competitive binding to the Hsp90 N-
terminal domain was observed in a biochemical assay, and these compounds showed antiproliferative activity and induced
apoptosis in the HCT116 human colon cancer cell line. These inhibitors also caused induction of the heat shock response
with the upregulation of Hsp72 and Hsp27 protein expression and the depletion of Hsp90 clients, CRAF, ERBB2 and CDK4,
thus confirming that antiproliferative activity was through the inhibition of Hsp90. The presence of increased levels of the
cleavage product of PARP indicated apoptosis in response to Hsp90 inhibitors. This work provides a framework for the
further optimization of thiadiazole inhibitors of Hsp90. Importantly, we demonstrate that the thiadiazole inhibitors display a
more limited core set of interactions relative to the clinical trial candidate NVP-AUY922, and consequently may be less
susceptible to resistance derived through mutations in Hsp90.
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Introduction
The molecular chaperone Hsp90 is responsible for the
maturation and activation of specific client proteins that are key
components of signal-transduction pathways that regulate growth
and proliferation. These clients include numerous oncogenic
proteins such as steroid-hormone receptors and kinases (ERBB2,
EGFR, ALK, CRAF, BRAF and CDK4). The ATPase activity of
Hsp90 is crucial for the activation of such client proteins. ATP
binding to the N-terminal domain of Hsp90 leads to a series of
structural changes that promote N-terminal dimerization [1],
while binding Hsp90 inhibitors that target the ATP binding site of
Hsp90 prevents these conformational changes and leads to the
degradation of its client proteins [2].
The natural antibiotic Hsp90-inhibitors, geldanamycin and
radicicol, target the N-terminal ATP-binding site of Hsp90.
Inhibition elicits proteosomal degradation of Hsp90 client-proteins
by a ubiquitination-mediated process, which may involve the E3
ubiquitin ligase CHIP [3]. Radicicol has no activity in vivo due to
its instability and geldanamycin displays significant toxicity that
precludes its use as an effective anticancer drug. This led to the
development of the geldanamycin derivative 17-allylamino-17-
demethoxy-geldanamycin (17-AAG, tanespimycin) [4,5,6], which
has shown clinical activity in phase I/II clinical trials [7,8,9,10].
Despite its clinical activity, most promisingly in trastuzumab-
refractory ErbB2-positive breast cancer [10], 17-AAG suffers from
a limited aqueous solubility, low oral bioavailability [10,11],
susceptibility to the metabolic activities of polymorphic enzymes
(CYP3A4 and NQO1/DT-diaphorase [5,12,13]), and hepatotox-
icity [7,8,9]. More water-soluble derivatives of geldanamycin, 17-
DMAG (alvespimycin) and IPI-504 (retaspimycin), have entered
clinical trials [10,14,15,16]. Currently, radicicol derivatives have
not entered clinical trial.
Cancer cells appear to be more susceptible to Hsp90 inhibition
than normal cells [17,18,19,20,21,22] and consequently there
have been considerable efforts to develop synthetic small molecule
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inhibitors against the ATP-binding site of Hsp90 [23,24]. The first
synthetic small molecule to be identified as a Hsp90 ATPase-
inhibitor was based on a purine scaffold [25,26]. Another class of
small molecules, the 3-4-diaryl pyrazole resorcinols, was then
identified. The pyrazoles are exemplified by the prototype
CCT018159 [27,28,29], and were further optimized to produce
the pyrazole- and isoxazole-amide resorcinol analogues [30,31],
from which the isoxazole NVP-AUY922 (VER52296, Fig. 1)
emerged as a clinical trial candidate that is now showing promise
in Phase II clinical trials [32,33,34]. These new agents overcome
many of the liabilities of the geldanamycin class, including
hepatotoxicity that could be attributed to the quinone group
[23,24].
While mechanisms of resistance to Hsp90 inhibitors have so far
not emerged in the clinic, it has been clearly demonstrated that
resistance to the natural product inhibitors, geldanamycin and
radicicol, is possible through mutation leading to altered amino-
acid residues in the ATP-binding site of Hsp90 [35,36]. Thus it
appears that the ATP-binding pocket of Hsp90, although highly
conserved, can nevertheless tolerate mutagenic changes leading to
resistance against these inhibitors. Potentially, such mutations may
eventually be seen in the clinic and consequently the development
of a variety of structurally diverse inhibitors, that interact purely
with highly conserved residues that form the central components
of the ATP-binding site of Hsp90, is all the more important. The
present series of the 5-aryl-4-(5-substituted-2-4-dihydroxyphenyl)-
1,2,3-thiadiazoles (ICPD 26, 34 and 47) were recently synthesized
(Fig. 1) and shown to be effective Hsp90 inhibitors in terms of
binding to Hsp90 [37]. The dissociation constant for the binding
of these inhibitors to full-length Hsp90a varied from 4.8 to
39.0 nM. Here we determine the molecular and structural
biological details of this inhibition, demonstrate using biomarkers
that these agents inhibit Hsp90 in cancer cells, and show that they
exhibit antiproliferative activity and induce apoptosis in the
human colon cancer cell line HCT116. Importantly, we demon-
strate that the thiadiazole inhibitors display a more limited core set
of interactions relative to the clinical trial candidate NVP-
AUY922, and consequently may be less susceptible to resistance
derived through mutations in the N-terminal ATP site of Hsp90.
Results
Protein X-ray Crystallography
ICPD 26, 34 and 47 (Fig. 1) essentially bind to Hsp90 in the
same way (Fig. 2 and Table 1). A crucial network of hydrogen
bonding between the resorcinol group and highly conserved
amino-acid residues, Leu 48, Ser 52, Asp 93, Gly 97 and Thr 184,
of the ATP-binding site is present as previously seen with pyrazole
Figure 1. Chemical strucures of the thiadiazole compounds and NVP-AUY922. The Kd values for binding to Hsp90 are indicated.
doi:10.1371/journal.pone.0044642.g001
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and isoxazole resorcinol inhibitors [27,28,32] (Fig. 2). Hydropho-
bic interactions that are also conserved include those with Asn 51,
Ala 55, Met 98 and Phe 138 (Fig. 2). The interaction between Gly
97 and the monoethylamide group of NVP-AUY922 has
previously shown to be important for the potency of this
compound [21,31]. The main-chain carbonyl group of Gly 97
does not form a hydrogen bond interaction with the ICPD
compounds (Fig. 2). Furthermore, the sulphur atom in the
thiadiazole ring of the ICPD compounds is not optimally
positioned to form an interaction with the carbonyl of Gly 197
(Fig. 2). The chlorine atom in ICPD 34 and ICPD 47 and the
interactions it makes has been previously explored with other
compounds containing chlorine at the same position. The
interactions made by the chlorine atom are consistent with these
reports [27,28,32].
Although the ICPD compounds bind Hsp90 in similar ways, the
Kd values for the binding of ICPD 26 and ICPD 47 (7.5 and
4.8 nM, respectively) and ICPD 34 (Kd= 39.0 nM) are very
different, with ICPD 34 being less potent (Fig. 1). ICPD 26 is
similar to ICPD 34, except that it lacks a 3-methoxy group (Fig. 1
and 2). The presence of this group in ICPD 34 has a profound
effect on a short mobile loop (Asp 105 to Ile 110) that consequently
adopts an open conformation and fails to interact with the bound
inhibitor (Fig. 3A). Furthermore, amino-acid residues 111–131
become completely disordered (Fig. 3A). With ICPD 26 and 47
this loop adopts a more compact conformation interacting with
the bound inhibitor. For a variety of pyrazole and isoxazole
inhibitors the conformation of the loop is either in an open (pdb
2BYI and 2BYH) or compact conformation (pdb 2CCU, 2VCJ,
2CCT, 2CCS, 2BSM and 2BT0). For the clinical trial candidate
NVP-AUY922 (pdb 2VCI) the loop is in the apparent favored
compact state. It therefore appears that the binding affinity of
ICPD 34 is negatively affected by having to promote a
conformational change that moves the short mobile loop to a
more open conformation and causes disorder in the amino-acid
residues from Asp 105 to Ile 110, and/or by failing to interact with
the loop itself. This could potentially explain the weaker binding of
ICPD 34, relative to ICPD 26 and 47 (Fig. 1–3). Consequently,
optimizing interactions between this mobile loop and future Hsp90
inhibitors could provide higher affinity binding inhibitors as has
Table 1. Crystallographic statistics.
Data Set
(Highest shell
in parentheses) ICPD 26 ICPD 34 ICPD 47
a (A˚) 65.430 70.870 65.230
b (A˚) 89.315 90.310 88.705
c (A˚) 100.090 88.440 99.625
a (u) 90.00 90.00 90.00
b (u) 90.00 90.00 90.00
c (u) 90.00 90.00 90.00
Space Group I222 C2221 I222
Wavelength (A˚) 0.97960 0.97960 0.97960
Resolution Limit (A˚) 53.0–1.6
(1.69–1.60)
56.0–2.50
(2.63–2.50)
45.0–1.40
(1.48–1.40)
Number of Obs. 38928 (5611) 10079 (1447) 57073 (8252)
Completeness (%) 99.8 (99.9) 99.6 (99.6) 99.8 (100.0)
Multiplicity 4.1 (3.8) 3.4 (3.5) 4.2 (3.9)
Rmrg (%) 0.057 (0.317) 0.083 (0.524) 0.047 (0.392)
I/sI 16.0 (4.0) 12.2 (2.3) 18.3 (3.3)
Refinement
Rcryst 0.199 0.2042 0.203
Rfree 0.234 0.2589 0.229
No. of protein atoms 1639 1616 1658
No. of ligand atoms 23 24 24
No. of solvent atoms 303 107 366
Mean B 18.6 43.2 14.0
Rmsd bond lengths (A˚) 0.020 0.020 0.017
Rmsd bond angles (u) 1.946 0.713 1.868
doi:10.1371/journal.pone.0044642.t001
Figure 2. PyMOL diagram showing binding interactions with
Hsp90. (A) Interactions of ICPD 34 and (B) ICPD 47 with the N-terminal
domain of human Hsp90a. Dotted blue lines represent hydrogen bonds
and the amino-acid residues involved are in green; cyan-colored
spheres represent water molecules and cyan residues are amino acids
solely in van der Waals contact. The structures for ICPD 34, and ICPD 47
were obtained at 2.5, and 1.4 A˚ resolution, respectively. ICPD 26, which
lacks a 3-methoxy group relative to ICPD 34, binds in essentially the
same manor as ICPD 34 and ICPD 47. For atomic coordinates and
structure factors, see PDB codes 2YI0 (ICPD 26), 2YI5 (ICPD 34), and 2YI7
(ICPD 47).
doi:10.1371/journal.pone.0044642.g002
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been observed for the morpholino- and monoethylamide-group of
NVP-AUY922 (pdb 2VCI). Such interactions should be directed
towards amino acid residues closest to the bound inhibitors, which
include the highly conserved Leu 107, Gly 108 and Thr 109
amino-acid residues. However, because these residues are found at
the periphery of the ATP-binding site they may be subject to
mutational changes that could result in resistance.
Resistance through mutagenesis of the ATP-binding site of
Hsp90 has recently been shown against both radicicol and
geldanamycin [35,36]. Interestingly, resistance to geldanamycin
involved amino acid changes (E88G and N92L) that are at the
Figure 3. PyMol cartoons of the structure of human Hsp90-drug complexes. (A), PyMol cartoon showing ICPD 34 (cyan) and NVP-AUY922
(yellow and magenta) bound to the N-terminal domain of human Hsp90a. The magenta region of the NVP-AUY922-Hsp90a complex represents the
unstructured region of the ICPD 34-Hsp90a complex. The mobile loop region interacting with NVP-AUY922 is shown in gold. Water molecules are
shown as cyan colored spheres and hydrogen bonds as dotted blue lines. The 3-methoxy group of ICPD 34 causes the loop represented by Asn 105
to Ile 110 to adopt an alternative conformation, which moves from the gold to green conformation. (B), Two orthogonal views of the superimposition
of ICPD 34 (Cyan) and NVP-AUY922 (yellow) showing that the compounds bind with overall similarity, except for the morpholino group of NVP-
AUY922 and the dimethoxyphenyl group of ICPD 34. The structures for ICPD 34 and NVP-AUY922 were obtained at 2.5 and 2.0 A˚ resolution,
respectively. For atomic coordinates and structure factors, see PDB codes 2YI5 and 2VCI, respectively.
doi:10.1371/journal.pone.0044642.g003
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entrance to the ATP-binding site of Hsp90. In contrast, resistance
to radicicol involved an amino acid change (L34I) at the base of
the ATP-binding pocket. However, because of the less bulky
nature of the thiadiazoles and the simpler set of interactions that
these compounds make with Hsp90, they have the potential to be
potent inhibitors in situations where more bulky compounds, such
as NVP-AUY922, may fail due to emerging resistance in Hsp90.
Together with their significant activity against Hsp90, the
structural data indicate that the thiadiazole inhibitors may
represent a very useful class of Hsp90 inhibitor.
Thiadiazoles Bind to Hsp90b and Inhibit Proliferation of
HCT116 Human Colon Cells
The thiadiazoles compounds were evaluated for binding to full-
length human Hsp90b and antiproliferative activity in cancer cells
using the fluorescence polarization (FP) and the sulforhodamine B
(SRB) assay, respectively (Table 2). Competitive binding as
measured by FP across the 3 compounds ranged from 14.6 to
51.9 nM, which were consistent with the measured Kd values
(Fig. 1). The compounds exhibited antiproliferative activity
(GI50 = 3.2 to 4.6 mM) against the HCT116 human colon cancer
cell lines (Table 2).
Thiadiazoles Elicit Depletion of Hsp90 Client Proteins,
Induction of Heat Shock Proteins and Apoptosis
To confirm that growth inhibition was due to the intended
Hsp90 inhibitory mechanism, the ICPD 26, 34 and 47 compounds
were assessed for their effects on the established molecular
signature of Hsp90 inhibition in the HCT116 cancer cells [38].
Depletion of client proteins CRAF, ERBB2 and CDK4, together
with upregulation of Hsp72 and Hsp27 expression was observed,
with a series of inhibitor concentrations, for the three compounds
currently available, ICPD 26, 34 and 47, thus confirming that
these compounds were acting as Hsp90 inhibitors in the cell
(Fig. 4). An increase in PARP cleavage indicated induction of
apoptosis.
Discussion
The thiadiazoles studied here were previously shown to have
significant affinity towards Hsp90, displaying Kd values ranging
from 4.8 and 39 nM [37]. Herein we have characterized the
molecular interactions that these inhibitors make with the Hsp90a
N-terminal ATP-binding domain and analyzed their effects on the
human colon cancer cell line HCT116. The X-ray structures
presented herein demonstrate that the thiadiazole compounds,
although chemically simpler and less bulky, are none-the-less
effective Hsp90 inhibitors. One of the inhibitors, ICPD 34, causes
a structural change that affects a mobile loop, which adopts a
conformation similar to that seen in complexes with ADP, rather
than the conformation generally seen with the pyrazole/isoxazole-
resorcinol class of inhibitors, such as NVP-AUY922. Importantly,
we demonstrate that the thiadiazole inhibitors display a more
limited core set of interactions relative to the clinical trial
candidate NVP-AUY922, and consequently may be less suscep-
tible to resistance derived through mutations in Hsp90. We have
not tested this possibility directly, as it is difficult to predict
precisely what mutations in Hsp90 might arise that would lead to
resistance. However, the possibility of avoiding resistance
combined with their antiproliferative and apopototic activity
mediated through Hsp90 inhibition, makes the thiadiazole
compounds an interesting and potentially useful class of Hsp90
inhibitors.
Interestingly, a conformational change in the main-chain of the
N-terminal domain was seen with ICPD 34, in order to
accommodate the 3-methoxy group on the benzyl ring of this
compound. It appears that the resulting conformation of the loop
upon binding of ICPD 34 lowers the binding affinity as compared
with ICPD 26 and ICPD 47, which lack the 3-methoxy group.
The additional interactions this group makes do not compensate
for the loss of the morpholino group, which for NVP-AUY922 is
involved in a series of interactions that contribute to the increased
potency of this compound [33].
The IC50 values for binding of the clinical candidate NVP-
AUY922 to Hsp90a and Hsp90b, as measured by the FP
competitive binding assay, were found to be 7.861.8 and
21616 nM, respectively [33]. In comparison, the thiadiazoles
displayed values ranging from 14.6 to 51.9 nM against Hsp90b,
results that are consistent with their somewhat weaker affinity
for Hsp90 relative to NVP-AUY922. Furthermore, the GI50
values for antiproliferative activity ranged between 3.2 to
4.6 mM, which are much higher than the values for NVP-
AUY922 (16.068.0 nM) against the HCT116 human colon
cancer cell line [33]. The molecular signature of Hsp90
inhibition is the induction of the molecular chaperones Hsp72
and Hsp27 combined with the depletion of Hsp90 client-
proteins. All three of the thiadiazole compounds tested displayed
this signature of Hsp90 inhibition (Fig. 4) and they also induced
PARP cleavage, suggesting that they induced apoptosis. The
greater cellular potency of NVP-AUY922 against the thiadia-
zoles may be due to cell permeability issues and it is
acknowledged that further optimization work is required to
convert the high potency on the molecular target into greater
potency against cancer cells. Such investment of effort can be
justified by their potential to avoid emerging mechanisms of
resistance due to mutations in the N-terminal ATP pocket.
In conclusion, apart from the relative simplicity of their
synthesis, the main potential advantage of the thiadiazole
compounds studied here is the limited number of interactions
that they make with highly conserved amino-acid residues
representing the core of the N-terminal ATP-binding site of
Hsp90. Consequently, they maybe less prone to resistance through
mutation of this ATP-binding site. Whether these compounds
could be developed further remains to be seen; however, this
present study provides the structural basis and mechanistic
framework to support further optimization.
Materials and Methods
Hsp90 Inhibitors
The synthesis of the 5-aryl-4-(5-substituted-2-4-dihydroxyphe-
nyl)-1,2,3-thiadiazoles was previously described [37]. The chem-
ical structures of the compounds studied here are shown in
Figure 1.
Table 2. Hsp90 binding and inhibitory activities.
Compound FP (IC50; nM) HCT116 SRB (GI50; mM)
ICPD 26 26.664.4 3.260.7
ICPD 34 51.966.4 4.660.4
ICPD 47 14.661.6 4.660.4
FP and SRB values are mean 6 SE of assays done in triplicate.
doi:10.1371/journal.pone.0044642.t002
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Crystallization, Crystallographic Data Collection and
Refinement
Crystals of human Hsp90a N-terminus were grown from a 1:1
mixture of protein (29 mg ml21) and precipitant solution
(0.2 M MgCl2, 25% PEG 2 K and 100 mM sodium cocodylate
pH 6.5) using the vapor diffusion crystallization method. The
crystals were stepwise cryoprotected in 30% glycerol and flash
frozen before data were collected at Diamond on beamline IO2.
Data were processed in Mosflm and scaled and merged using
SCALA [39]. The structure was solved by molecular replacement
with Phaser using pdb code 2WI1 for compounds ICPD 26, and
47, and PDB code 1YC1 for ICPD 34 as the search model. The
structures were refined using Phenix, with weight optimization,
and manual building using COOT [40,41,42]. The inhibitors
were built using the PRODRG5 server. The ligand and waters
were added towards the end of refinement. Structures were
submitted to PUBSUM [43] for determination of molecular
interactions between the protein and the drug molecules, in
addition to visual inspection with PyMol [44]. The statistics for the
crystallographic determinations are shown in Table 1 and the co-
ordinates for the structures were deposited in the pdb database.
The pdb accession numbers are 2YI0 (ICPD 26), 2YI5 (ICPD 34),
and 2YI7 (ICPD47).
Cell Lines
The human colon cancer cell line HCT116 was obtained from
the American Type Culture Collection (LGC Promochem,
Middlesex, UK). Cells were grown in DMEM/10% FCS, 2 mM
glutamine and nonessential amino acids in 5% CO2. HCT116
cells were free of Mycoplasma contamination (Venor GeM kit,
Minerva Biolabs, Berlin, Germany).
Production of Recombinant Proteins
The N-terminal domain of Hsp90a [45] and the full length
Hsp90b proteins were overexpressed in E. coli and purified as
previously described [46,47].
Western Blots
Protein extracts were prepared and Western blotting was
performed as previously described [5,31].
Fluorescence Polarization and Growth Inhibition Assay
Binding of HSP90 inhibitors to human full-length HSP90b was
determined by a competitive binding fluorescence polarization
assay, using a fluorescent isoxazole- resorcinol probe, as described
previously [48]. Briefly, compounds were assayed in a 96-well
plate format to determine IC50 values. Reaction mix (100 ml;
100 mM Tris.Cl, pH 7.4, 20 mM KCl, 6 mM MgCl2,
5 mg ml21 bovine serum albumin, 80 nM isoxazole probe,
100 nM Hsp90b) was added per well of a black 96-well plate
(Corning Costar No. 3915) and allowed to equilibrate for 20 min
at room temperature in the dark. Plates were read on a Fusion
Alpha-FP (Perkin–Elmer, USA) with excitation 485/20 nM and
emission 535/25 nM with polarization. Compounds at a range of
concentration were then added to the reaction, mixed thoroughly,
and allowed to equilibrate again at room temperature in the dark
for 20 min. IC50 values were calculated on the difference in
anisotropy from the first and second reads.
Figure 4. The biomarker signature of Hsp90 inhibition. Western blot showing depletion of Hsp90 client proteins and induction of Hsp72,
Hsp27 and cleaved PARP, upon treatment with 16, 56and 106GI50 concentrations of compounds in HCT116 human colon cancer cells for 24 hr. 17-
AAG was used as a positive control. Gapdh was used as loading control. Induction of cleaved PARP is also shown and is indicative of apoptosis.
doi:10.1371/journal.pone.0044642.g004
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Sensitivity of cells to Hsp90 inhibitors was measured by the
sulforhodamine B (SRB) assay [5]. Briefly, cells were seeded into
96-well microtiter plates and allowed to attach for 36 hours.
Compounds at a range of concentrations were added in
quadruplicate wells for 4 days in a volume of 200 ml per well.
The GI50 was calculated as the drug concentration that inhibits
cell proliferation by 50% compared with vehicle controls.
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